Nektar Therapeutics regains Nasdaq minimum bid price compliance

NEKTAR THERAPEUTICS

Received Nasdaq notice on April 17, 2024, confirming compliance regained as of April 16, 2024.
Common stock closing bid price met $1.00 minimum for 10 consecutive business days.
Stock had been non-compliant since May 2023 and transferred to Nasdaq Capital Market in November 2023.
Additional 180-day extension had been granted until May 20, 2024.
Continued listing on Nasdaq Capital Market is now secure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.